Cholecystokinin

Overview

Cholecystokinin (CCK) is a peptide hormone produced by enteroendocrine I cells in the mucosa of the duodenum and jejunum, and a neuropeptide expressed widely in the central and peripheral nervous systems. Its name derives from the Greek for "gallbladder-moving" (chole = bile, cysto = bladder, kinin = move), reflecting its original identification in 1928 by Ivy and Oldberg as the humoral factor responsible for gallbladder contraction in response to fat in the duodenum.

CCK is one of the most abundant neuropeptides in the mammalian brain and serves dual functions as a gut hormone regulating digestion and a neurotransmitter modulating satiety, anxiety, pain perception, and memory. This dual peripheral-central role positions CCK at the interface of the gut-brain axis, coordinating both the mechanical and behavioral components of the feeding response.

Like Gastrin, CCK belongs to the gastrin-CCK peptide family, sharing a C-terminal pentapeptide amide sequence (Gly-Trp-Met-Asp-Phe-NH2). This shared motif enables both peptides to bind CCK/gastrin receptors, though with different affinities and tissue distributions.

Structure and Molecular Forms

CCK exists in multiple bioactive forms derived from post-translational processing of a 115-amino-acid prepro-CCK precursor:

• CCK-58: 58 amino acids; the predominant circulating form in many species
• CCK-33: 33 amino acids; a major circulating form in humans
• CCK-22: 22 amino acids
• CCK-8: 8 amino acids; the most potent and commonly studied form; retains full biological activity
• CCK-4: C-terminal tetrapeptide (Trp-Met-Asp-Phe-NH2); minimal active fragment; potent anxiogenic

Critical modification: Tyrosine sulfation at position 7 of CCK-8 (Tyr-SO3) is essential for high-affinity CCK1 receptor binding. The sulfated form (CCK-8S) is approximately 1,000-fold more potent than the non-sulfated form at CCK1 receptors. This sulfation requirement distinguishes CCK from Gastrin, which binds CCK2 receptors independent of sulfation status.

Receptor Pharmacology

CCK signals through two G-protein-coupled receptors:

CCK1 Receptor (formerly CCK-A)

• Distribution: Gallbladder smooth muscle, pancreatic acinar cells, pyloric sphincter, vagal afferent neurons, select brain regions (nucleus tractus solitarius, area postrema)
• Selectivity: High affinity for sulfated CCK-8 (Kd ~50 pM); 500-1,000-fold selectivity over gastrin
• Signaling: Gq-coupled; phospholipase C activation, IP3/calcium mobilization, PKC activation
• Functions: Gallbladder contraction, pancreatic enzyme secretion, sphincter of Oddi relaxation, satiety signaling via vagal afferents

CCK2 Receptor (formerly CCK-B)

• Distribution: Gastric ECL cells, parietal cells, widespread in CNS (cortex, hippocampus, amygdala, brainstem)
• Selectivity: Approximately equal affinity for CCK and gastrin; sulfation not required
• Signaling: Gq-coupled; calcium/PKC pathway
• Functions: Gastric acid secretion (via histamine release from ECL cells), anxiety modulation, pain processing, memory

Physiological Functions

Gastrointestinal

Gallbladder contraction: CCK is the primary hormonal stimulus for gallbladder contraction and bile release into the duodenum. Released in response to dietary fat and protein in the duodenal lumen, CCK acts on CCK1 receptors on gallbladder smooth muscle to induce contraction, delivering bile salts for lipid emulsification.

Pancreatic enzyme secretion: CCK acts on CCK1 receptors on pancreatic acinar cells to stimulate secretion of digestive enzymes (trypsinogen, chymotrypsinogen, lipase, amylase). This action complements Secretin-stimulated bicarbonate secretion from ductal cells, providing both the enzymes and the optimal pH environment for nutrient digestion.

Gastric emptying regulation: CCK slows gastric emptying by contracting the pyloric sphincter and reducing gastric motility, allowing adequate time for duodenal digestion and nutrient absorption.

Satiety and Appetite

CCK is one of the earliest identified satiety signals. Peripheral CCK released postprandially activates CCK1 receptors on vagal afferent neurons in the gut wall, transmitting satiety signals to the brainstem (nucleus tractus solitarius) and hypothalamus. This contributes to meal termination and portion size regulation.

CCK1 receptor knockout mice demonstrate increased meal size, confirming the physiological role of CCK in limiting food intake. However, CCK primarily affects meal size rather than meal frequency, and compensatory mechanisms prevent CCK-based interventions from producing sustained weight loss.

Central Nervous System

As a neuropeptide, CCK modulates:

• Anxiety: CCK-4 (the C-terminal tetrapeptide) is one of the most potent panicogenic agents known; intravenous administration in humans reliably induces panic attacks; CCK2 receptor antagonists have been explored as anxiolytics
• Pain modulation: CCK acts as an endogenous anti-opioid peptide, counteracting opioid-mediated analgesia; CCK receptor antagonists can potentiate opioid analgesia
• Dopamine regulation: CCK co-localizes with dopamine in mesolimbic neurons and modulates dopaminergic neurotransmission within reward circuitry
• Memory: Hippocampal CCK release facilitates memory consolidation

Clinical Relevance

Diagnostic Use

Synthetic CCK-8 (sincalide, Kinevac) is used as a diagnostic agent to stimulate gallbladder contraction during hepatobiliary scintigraphy (HIDA scan) to calculate gallbladder ejection fraction, aiding in the diagnosis of functional gallbladder disorders.

Therapeutic Investigation

• CCK1 receptor agonists: Explored for obesity and appetite control; limited by short duration of satiety effect and gastrointestinal side effects
• CCK2 receptor antagonists: Investigated for anxiety disorders, panic disorder, and opioid analgesia potentiation
• Devazepide and loxiglumide: Experimental CCK receptor antagonists studied in various gastrointestinal and psychiatric conditions

Pathological Associations

• Gallstone disease: Impaired CCK-mediated gallbladder motility contributes to biliary stasis and stone formation
• Functional gallbladder disorder: Reduced gallbladder ejection fraction in response to CCK stimulation
• Pancreatic insufficiency: Impaired CCK signaling may contribute to exocrine pancreatic dysfunction

Dosing Protocols

As an endogenous gastrointestinal hormone, cholecystokinin is not typically administered exogenously in routine clinical practice. Synthetic CCK-8 (sincalide, marketed as Kinevac) is FDA-approved as a diagnostic agent for gallbladder function testing (cholecystokinin-stimulated cholescintigraphy) at a dose of 0.02 mcg/kg IV over 30-60 minutes. CCK is otherwise studied as a biomarker of satiety signaling and through receptor-targeted interventions in pain and anxiety research.

Scientific Significance

CCK exemplifies the concept of the gut-brain axis, functioning simultaneously as a digestive hormone and a neuromodulator. Its role as an endogenous anti-opioid peptide has significant implications for pain management, and its panicogenic properties have made it an essential tool in anxiety research. The CCK system's interaction with other regulatory peptides including Gastrin, Neurotensin, and Neuropeptide Y illustrates the complex peptidergic networks that coordinate feeding behavior and energy homeostasis.